How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
about
Advances in Diagnosis and Treatments for Immune ThrombocytopeniaRole of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopeniaLong-term safety and efficacy of romiplostim for treatment of immune thrombocytopeniaImmune thrombocytopeniaLaparoscopic splenectomy for primary immune thrombocytopenia: Current status and challengesSplenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopeniaManagement of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologistsITP: hematology's Cosette from Les Misérables.Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia.Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Immune thrombocytopenia -- what are the new treatment options?Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia.Autoimmune cytopenias in chronic lymphocytic leukemia.Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.Contemporary treatment of immune thrombocytopenia.Diagnosis and management of autoimmune cytopenias in childhood.Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia.The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.Management of thrombocytopenia.Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura?Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012.Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopeniaPhytochemicals as potential therapeutics for thrombocytopenia.Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study.The management of immune thrombocytopenic purpura.Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.Comparison between IV immune globulin (IVIG) and anti-D globulin for treatment of immune thrombocytopenia: a randomized open-label study.Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines.Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP.
P2860
Q26738630-10ADD7C9-A060-4DCA-8D11-84301CCE004BQ26741269-CBAB2669-855C-4DE8-93D5-E8BD774C0E28Q26745753-5F1B34B2-1417-44A0-B5C8-2CDDA66CEF7BQ26830918-2858875C-C11D-4744-A634-1216EB479B03Q28066579-184964E5-22FF-452B-B4A7-0B15405EED65Q33404320-89C08291-7E4A-4351-8BD3-563D598ACF64Q33406127-820ED1C0-E40B-4EFE-80A5-32F3404CAC9CQ33406264-293A8A09-2791-44B2-BFB8-AC0C91C65753Q33406470-B055E9BB-D451-4F10-8FE9-9D080A597156Q33407096-0E82D94F-A7A2-4E2E-ABB4-F7C6FA64124FQ33407110-4472813A-4F3D-4231-A71F-F6924D35966AQ33407802-0C9E6850-3034-412A-A84A-FAEDB7A46DA8Q33407831-9C3FD674-ED87-4E0C-9788-0F861EDF2A64Q33407866-6B51B0F6-3CE4-40DF-BFC8-E26B931D680FQ33408621-322592C9-BB0B-4034-AD8C-7ADB34D03B5DQ33410348-97AA97A0-80F3-427A-AC1B-AF930DD9D127Q33410653-6DC5869D-62DB-4820-813C-72C7918E7286Q33411497-AA9D2DD3-E6CC-4359-B5AD-EE904C356EBFQ33412766-1E29A7E3-0D75-41B5-B2C1-92DA31AEB98AQ33414573-0130F153-3787-4042-8AF9-36A8EC76430CQ33414722-F37B086E-5545-466D-822C-A9065A244D1EQ33416258-3EA55E30-8C31-479F-A3FE-4121A10212BDQ33416359-7A24CFC9-DF0F-4836-BB99-53FBD095B939Q33417946-EEF2FB57-20EE-4C7C-BB58-7FF1C799DEE2Q33418391-0E5B33AD-F1EA-4BA6-936F-0DEB7C257102Q33419605-C1FE5582-2797-4BA1-810D-8F23C12DACB9Q33419712-09DF06C3-6281-47F0-A51C-4BC5480C8EF3Q33419763-1FEB9617-01D3-4DB8-9520-F7B9EDC458F3Q33421585-E015B664-DF1A-4198-8B71-B7523CD63B84Q33424537-7ED226BF-1427-4667-A8E4-98CA6F09B30CQ33425035-EB0CC5E3-EDD2-443B-863D-F8DF766EF687Q33427336-CD7888B6-9D1B-45AB-8BEA-077B0D5636D5Q33427488-A0D566CB-B471-4EFA-AA57-E534CF2ABC79Q33428804-4270BD10-8223-41DF-9090-0577C4D1F167Q33429426-CFB173B7-09A1-4056-9949-A63DAA17716DQ33430843-43936612-E1DB-4192-9998-0727BB44CE39Q33431198-ED83C455-1B59-428A-AAE6-104A8F3A4C36Q33431635-70BFC04F-FE30-4FCC-9FF5-1AA44F6F3F8DQ33431689-481902FC-5526-4C5D-AAB2-F4CAC4B7D387Q33433585-2826A665-C175-40ED-8A5E-50E8DD8B9355
P2860
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
How I treat immune thrombocyto ...... apy as a second-line treatment
@ast
How I treat immune thrombocyto ...... apy as a second-line treatment
@en
How I treat immune thrombocyto ...... apy as a second-line treatment
@nl
type
label
How I treat immune thrombocyto ...... apy as a second-line treatment
@ast
How I treat immune thrombocyto ...... apy as a second-line treatment
@en
How I treat immune thrombocyto ...... apy as a second-line treatment
@nl
prefLabel
How I treat immune thrombocyto ...... apy as a second-line treatment
@ast
How I treat immune thrombocyto ...... apy as a second-line treatment
@en
How I treat immune thrombocyto ...... apy as a second-line treatment
@nl
P3181
P1433
P1476
How I treat immune thrombocyto ...... apy as a second-line treatment
@en
P2093
D. B. Cines
P3181
P356
10.1182/BLOOD-2011-12-309153
P407
P577
2012-08-02T00:00:00Z